Express Improved antibody-coupled drugs target a variety of solid tumors, and the new sharp completed a $68 million Series A financing

Pheon Therapeutics recently announced the completion of a $68 million Series A funding round
.
The funds obtained will be used to advance Pheon's major antibody-conjugated drug (ADC) program into clinical proof-of-concept trials and to establish another pipeline of innovative antibody-conjugated drugs
.

Antibody-conjugated drugs comprise antibodies connected by chemical hymens and cytotoxic loaded drugs
.
The antibody part of the drug can target the target protein on the surface of the cancer cell, and enter the cell through the endocytosis of the cell, releasing the poison killing drug in the cancer cell, and then achieving the purpose of
killing the cancer cell.
Antibody-conjugated drugs are rapidly developing clinically and commercially, and until now, more than 100 antibody-conjugated drugs are undergoing clinical trials
.

Pheon's proprietary antibody-coupled drug development platform improves on existing technology to enable the drugs it develops to benefit more patients, one of which is a cancer target that targets innovation
.
Pheon has a number of exclusive in vivo conceptually validated potential "first-in-class" solid tumor projects that have been thoroughly analyzed
for expression of potential targets in tumors and normal tissues.
Pheon also has proprietary, innovative payloads of anti-virus drugs that have the potential to overcome cancer cell resistance
to existing approved anti-cancer, antibody-conjugated drugs.
While many of these approved drugs are based on traditional toxin-killers, Pheon's payload drugs have innovative pharmacological mechanisms and their potency does not depend on the mitotic index of cancer cells
.
It is worth mentioning that the antibody-conjugated drugs developed by Pheon are connected to the drug by the spot-type hymen, which has a controllable poisoning ability, that is, the type of loaded drug or the ratio of drug to antibody (DAR) can be adjusted
according to different purposes such as target and indication.

Pheon's main project, PHN-010, targets a target that is highly expressed in many solid tumors (target names have not yet been revealed) and is expected to file for a new drug clinical trial (IND) application
over the next 18 months.
Another of its projects, PHN-020, which targets solid tumors, is still in the early stages of
preclinical development.

Mr.
Bertrand Damour, CEO of Pheon, said: "The potential 'first-in-class' antibody conjugated drugs that Pheon is developing are built on a proprietary platform that is different and is a huge impetus
to move the project forward.
We are currently focused on executing strategies to advance our first project into clinical development as quickly as possible, and the preclinical data we have obtained so far is remarkable
.
The experience and expertise of our leadership team is outstanding, and I'm proud
to work with them and work with them to develop this innovative approach into therapies for cancer patients.
" ”

WuXi AppTec provides integrated, end-to-end new drug development and manufacturing services to the global biopharmaceutical industry, covering the fields
of chemical drug development and production, biological research, preclinical testing and clinical trial development, cell and gene therapy development, testing and production.
If you have relevant business needs, please click on the picture below to fill in the specific information
.